226 related articles for article (PubMed ID: 37496441)
1.
Nylund P; Garrido-Zabala B; Párraga AA; Vasquez L; Pyl PT; Harinck GM; Ma A; Jin J; Öberg F; Kalushkova A; Wiklund HJ
Haematologica; 2024 Feb; 109(2):567-577. PubMed ID: 37496441
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
3. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
4. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
[TBL] [Abstract][Full Text] [Related]
5. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
6. PVT1 signals an androgen-dependent transcriptional repression program in prostate cancer cells and a set of the repressed genes predicts high-risk tumors.
Videira A; Beckedorff FC; daSilva LF; Verjovski-Almeida S
Cell Commun Signal; 2021 Jan; 19(1):5. PubMed ID: 33430890
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody raised against human EZH2 cross-reacts with the RNA-binding protein SAFB.
Cherney RE; Mills CA; Herring LE; Braceros AK; Calabrese JM
Biol Open; 2023 Jun; 12(6):. PubMed ID: 37283223
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
9. lncRNA PVT1 promotes hepatitis B virus‑positive liver cancer progression by disturbing histone methylation on the c‑Myc promoter.
Jiang B; Yang B; Wang Q; Zheng X; Guo Y; Lu W
Oncol Rep; 2020 Feb; 43(2):718-726. PubMed ID: 31894346
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
11. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
12. Ppp1r1b-lncRNA inhibits PRC2 at myogenic regulatory genes to promote cardiac and skeletal muscle development in mouse and human.
Kang X; Zhao Y; Van Arsdell G; Nelson SF; Touma M
RNA; 2020 Apr; 26(4):481-491. PubMed ID: 31953255
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA PVT1 indicates a poor prognosis of glioma and promotes cell proliferation and invasion via target EZH2.
Yang A; Wang H; Yang X
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29046366
[TBL] [Abstract][Full Text] [Related]
14. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma.
Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N
Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).
Zhou Q; Chen J; Feng J; Wang J
Tumour Biol; 2016 Mar; 37(3):3105-13. PubMed ID: 26427660
[TBL] [Abstract][Full Text] [Related]
17. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
[TBL] [Abstract][Full Text] [Related]
18. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
19. Cryptic RNA-binding by PRC2 components EZH2 and SUZ12.
Betancur JG; Tomari Y
RNA Biol; 2015; 12(9):959-65. PubMed ID: 26177152
[TBL] [Abstract][Full Text] [Related]
20. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Herviou L; Kassambara A; Boireau S; Robert N; Requirand G; Müller-Tidow C; Vincent L; Seckinger A; Goldschmidt H; Cartron G; Hose D; Cavalli G; Moreaux J
Clin Epigenetics; 2018 Oct; 10(1):121. PubMed ID: 30285865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
